Objective To analyze the actual improvement effect of type 2 diabetes mellitus(T2DM)treated with dapa-gliflozin combined with dipeptidyl peptidase-4(DPP-4)inhibitor.Methods 100 cases of T2DM patients were se-lected as study objects in Fuzhou Economic and Technological Development Zone Hospital from February 2020 to March 2023,and were divided into a reference group(50 cases of metformin+DPP-4 inhibitor)and an observation group(50 cases of metformin+DPP-4 inhibitor+dapagliflozin)according to the previous treatment programs.The rate of adverse drug reactions,serum creatinine(Scr),blood uric acid(BUA),total cholesterol(TC),triglyceride(TG),2 h postprandial plasma glucose(2 hPG),fasting plasma glucose(FPG)were compared.Results After treatment,BUA[(302.56±38.28)μmol/L],TC[(4.29±0.74)mmol/L],TG[(1.43±0.44)mmol/L],2 hPG[(9.32±0.42)mmol/L],FPG[(6.42±0.15)mmol/L]of patients in the observation group were lower than those in the reference group,the differences were statistically significant(t=2.023,5.235,2.284,6.515,26.524,all P<0.05).There were no statistically significant differences in the Scr index and the rate of adverse drug reactions between two groups(both P>0.05).Conclusion Dapagliflozin combined with DPP-4 inhibitor has excellent effect in T2DM treatment.
Type 2 diabetes mellitusDapagliflozinDPP-4 inhibitorBlood glucose indexesRenal functionBlood lipid indexes
NETL
NSTL
万方数据
